Learn more about what Meitheal Pharmaceuticals is doing to deliver on its vision of Healthcare Solutions within reach.

Watch Video

Committed to Affordability and Accessibility in the U.S. Market through Development and Acquisition.

Our FDA-approved medications reflect our enduring dedication to improving treatment accessibility and outcomes for patients with life-changing illnesses. Our corporate vision, "Healthcare Solutions Within Reach," drives Meitheal to invest significant resources in bringing medicines to market, enhancing access and affordability, and improving patient outcomes. Click the links below to access the complete U.S. Prescribing Information, including the Medication Guide.

Autoimmune Disease Therapies

Our Pipeline


Drug Name Therapeutic Area Type Discovery Preclinical Phase 1 Phase 2 Phase 3 Submission
MAB-22 Oncology Biosimilar
Insulin Aspart Diabetes Biosimilar
Insulin Glargine Diabetes Biosimilar
Insulin Lispro Diabetes Biosimilar
Find answers to commonly asked questions about biosimilar medicines.

A biosimilar is a complex medicine that is highly similar to the brand name biologic it references, and does not have any clinically meaningful differences in safety, purity, or potency.

Biologic medicines are complex medicines made from living cells.

Biosimilars are used to treat a variety of diseases, like rheumatoid arthritis, Crohn’s disease, and cancer. They are the generic competitors to more expensive brand biologic medicines.

All biologic products, including biosimilars, must meet the rigorous safety and efficacy standards set by the U.S. Food and Drug Administration (FDA).

An interchangeable designation is unique to the United States, and is not an indication of superior quality. This designation allows a pharmacist, subject to state law, to substitute and dispense a biosimilar when a patient’s doctor prescribed the reference biologic.

A reference product is the single biologic product, already approved by FDA, against which a proposed biosimilar product is compared.

No, generic medicine and the original brand small molecule product are produced by chemical processes. A biosimilar medicine is a highly similar version of an original brand of a biological medicine.

In the United States, all biosimilars must meet the safety and efficacy standards set by the FDA before they are made available to patients. Biosimilars must prove that they can treat a patient with no clinically meaningful differences from the reference product in terms of safety, purity and potency.

Your doctor and healthcare team are always your best source of information. For information about specific biologic or biosimilar medicines, you can browse the FDA’s website here. Our Helpful Links page lists additional resources we hope you find useful.

Download Information
You might also be interested

The brands mentioned here are the trademarks of their respective owners.

This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices